Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to extend life in advanced lung cancer

NCT ID NCT04380636

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drugs pembrolizumab and olaparib to standard chemoradiation helps people with stage III non-small cell lung cancer live longer without their cancer growing. About 870 participants will receive one of three treatments: pembrolizumab with chemoradiation and a placebo, pembrolizumab with chemoradiation and olaparib, or the current standard therapy (durvalumab after chemoradiation). The goal is to see which combination works best while monitoring side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 870 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2020

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has pathologically (histologically or cytologically) confirmed diagnosis of NSCLC * Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8 * Is unable to undergo surgery with curative intent for Stage III NSCLC * Has no evidence of metastatic disease indicating Stage IV NSCLC * Has measurable disease as defined by RECIST 1.1 * Has not received prior treatment (chemotherapy, targeted therapy or radiotherapy) for Stage III NSCLC; participants who have received neoadjuvant and/or adjuvant therapy for early stage disease are not eligible * Has provided a tumor tissue sample (tissue biopsy \[core, incisional, or excisional\]) * Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 assessed within 7 days prior to the first administration of study intervention * Has a life expectancy of at least 6 months * A male participant must agree to use contraception and refrain from donating sperm during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention unless confirmed to be azoospermic (vasectomized or secondary to medical cause). The length of time required to continue contraception for each study intervention is as follows: Olaparib, platinum doublet, and radiotherapy: 90 days * A female participant is eligible to participate if she is not pregnant, not breastfeeding, and agrees to use contraception and refrain from donating eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during the treatment period and for at least the time needed to eliminate each study intervention after the last dose of study intervention and agrees to abstain from breastfeeding during the study intervention period and for at least 120 days after the last dose of study intervention. The length of time required to continue contraception for each study intervention is as follows: Pembrolizumab: 120 days; Olaparib, platinum doublet, and radiotherapy: 180 days * Has a negative highly sensitive pregnancy test (\[urine or serum\] as required by local regulations) within 24 hours for urine or within 72 hours for serum before the first dose of study intervention. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. * Has had her medical history, menstrual history, and recent sexual activity reviewed by the investigator to decrease the risk for inclusion of a woman with an early undetected pregnancy. * Has adequate pulmonary function tests * Has adequate organ function * Has provided written informed consent Exclusion Criteria: * Has small cell lung cancer or a mixed tumor with presence of small cell elements * Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or has features suggestive of MDS/AML * Has had documented weight loss \>10% (from baseline) in the preceding 3 months * Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or for breast cancer * Has received prior therapy with an anti-programmed cell death 1 (ant-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti- programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor * Has received prior therapy with olaparib or with any other polyadenosine 5'diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor * Has had major surgery \<4 weeks prior to the first dose of study treatment (except for placement of vascular access) * Is expected to require any other form of antineoplastic therapy, while on study * Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention; administration of killed vaccines is allowed * Has received colony-stimulating factors (e.g., granulocyte colony-stimulating factor \[GCSF\], granulocyte-macrophage colony-stimulating factor \[GM-CSF\] or recombinant erythropoietin) within 28 days prior to the first dose of study treatment * Is currently receiving either strong (phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate (e.g. bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be discontinued for the duration of the study * Is currently receiving either strong (eg, itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study * Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 grams per day, for at least 2 days before, during, and for at least 2 days after administration of pemetrexed * Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone during administration of pemetrexed * Has received an investigational agent or has used an investigational device within 4 weeks prior to study treatment * The presence of uncontrolled, potentially reversible cardiac conditions, as judged by the investigator or has congenital long QT syndrome * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention * Has a known additional malignancy that is progressing or has required active treatment within the past 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ (excluding carcinoma-in situ-of the bladder) that have undergone potentially curative therapy * Has severe hypersensitivity (≥Grade 3) to study intervention and/or any of its excipients * Has an active autoimmune disease that has required systemic treatment in past 2 years * Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * Has an active infection requiring systemic therapy * Has a known history of human immunodeficiency virus (HIV) infection * Has a known history of Hepatitis B or known active Hepatitis C virus infection * Has active tuberculosis (TB; Mycobacterium tuberculosis) and is receiving treatment * Has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator * Is considered a poor medical risk due to a serious, uncontrolled medical disorder or nonmalignant systemic disease in the opinion of the treating investigator * Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study * Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption * Has had an allogenic tissue/solid organ transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung Lung neoplasms

Contacts and locations

Locations

  • A.O.U. Santa Maria della Misericordia di Udine ( Site 1004)

    Udine, 33100, Italy

  • Ajou University Hospital ( Site 2803)

    Suwon, Kyonggi-do, 16499, South Korea

  • Akershus Universitetssykehus HF ( Site 1106)

    Lorenskog, Akershus, 1478, Norway

  • Ankara Bilkent Sehir Hastanesi ( Site 2002)

    Ankara, Adana, 06800, Turkey (Türkiye)

  • Azienda Ospedaliera Umberto I- Torrette ( Site 1009)

    Torrette, Ancona, 60126, Italy

  • Azienda Ospedaliera Vito Fazzi ( Site 1003)

    Lecce, 73100, Italy

  • Azienda Ospedaliero Universitaria Careggi ( Site 1001)

    Florence, 50134, Italy

  • Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 2302)

    Kecskemét, Bács-Kiskun county, 6000, Hungary

  • Beijing Cancer Hospital ( Site 3212)

    Beijing, Beijing Municipality, 100089, China

  • Beijing Cancer Hospital ( Site 3224)

    Beijing, Beijing Municipality, 130021, China

  • Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 2303)

    Gyula, Bekes County, 5700, Hungary

  • Bradford Hill Norte ( Site 0204)

    Antofagasta, 1240000, Chile

  • Bradfordhill ( Site 0200)

    Santiago, Region M. de Santiago, 8420383, Chile

  • C.H.R.U. de Brest - Hopital Cavale Blanche ( Site 0806)

    Brest, Brittany Region, 29200, France

  • CHD Vendee ( Site 0807)

    La Roche-sur-Yon, Vendee, 85925, France

  • CHI Health St. Francis ( Site 0053)

    Grand Island, Nebraska, 68803, United States

  • CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0108)

    Montreal, Quebec, H3T 1M5, Canada

  • CLIMERS Clinical Medical Research ( Site 0506)

    Orizaba, Veracruz, 94300, Mexico

  • Cancer Care Northwest ( Site 0074)

    Spokane Valley, Washington, 99216, United States

  • Cancer Hospital Chinese Academy Of Medical Sciences. Shenzhen Center ( Site 3200)

    Shenzhen, Guangdong, 518116, China

  • Cancer Hospital Chinese Academy of Medical Sciences ( Site 3213)

    Beijing, Beijing Municipality, 100021, China

  • Cancer Institute Hospital of JFCR ( Site 3107)

    Tokyo, 135-8550, Japan

  • Centre Hospitalier Annecy Genevois ( Site 0811)

    Epagny Metz Tessy, Haute-Savoie, 74730, France

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0102)

    Montreal, Quebec, H2X 0A9, Canada

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0110)

    Québec, Quebec, G1J 1Z4, Canada

  • Centro Investigación del Cáncer James Lind ( Site 0202)

    Temuco, Araucania, 4800827, Chile

  • Centrul de Oncologie Sfantul Nectarie-Medical ( Site 2510)

    Craiova, Dolj, 200746, Romania

  • Charite-Universitaetsmedizin Berlin Campus Virchow-Klinikum ( Site 0900)

    Berlin, 13353, Germany

  • Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1913)

    Chelyabinsk, Chelyabinsk Oblast, 454087, Russia

  • Chiang Mai University Maharaj Nakorn Chiang Mai Hospital ( Site 3001)

    Chiang Mai, 50200, Thailand

  • Christie NHS Foundation Trust ( Site 1409)

    Manchester, M20 4BX, United Kingdom

  • Chulalongkorn University ( Site 3003)

    Bangkok, Bangkok, 10330, Thailand

  • Chungbuk National University Hospital ( Site 2802)

    Cheongju-si, North Chungcheong, 28644, South Korea

  • Clinica Adventista Belgrano-Oncology ( Site 4002)

    Caba., Buenos Aires, C1430EGF, Argentina

  • Clinica San Gabriel ( Site 0601)

    Lima, 15088, Peru

  • Clinique Clairval ( Site 0802)

    Marseille, Bouches-du-Rhone, 13009, France

  • Clinique Teissier Groupe ( Site 0808)

    Valenciennes, Nord, 59304, France

  • Clinique de l'Europe-Service de pneumologie ( Site 0816)

    Amiens, Somme, 80000, France

  • Communal nonprofit enterprise "Kherson Regional Oncology Dispensary" of Kherson Regional Council ( Site 2109)

    Antonivka Village, Kherson Oblast, 73000, Ukraine

  • Daping Hospital,Third Military Medical University ( Site 3235)

    Chongqing, Chongqing Municipality, 400042, China

  • Detecta Clínica ( Site 0607)

    Surquillo, Muni Metro de Lima, 15038, Peru

  • Duke University Medical Center ( Site 0050)

    Durham, North Carolina, 27710, United States

  • Ege University Medical Faculty ( Site 2005)

    Izmir, 35100, Turkey (Türkiye)

  • Fakultni nemocnice Kralovske Vinohrady-Radioterapeuticka a onkologicka klinika ( Site 2200)

    Prague, Praha 10, 100 34, Czechia

  • Fakultni nemocnice Ostrava ( Site 2201)

    Ostrava, Ostrava Mesto, 708 52, Czechia

  • Fakultni nemocnice v Motole ( Site 2210)

    Prague, Praha 5, 150 006, Czechia

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1008)

    Milan, 20133, Italy

  • Fort Wayne Medical Oncology and Hematology ( Site 0094)

    Fort Wayne, Indiana, 46804, United States

  • Fox Chase Cancer Center ( Site 0063)

    Philadelphia, Pennsylvania, 19111, United States

  • Franciscan Health Lafayette East ( Site 0031)

    Lafayette, Indiana, 47905, United States

  • Fujian Provincial Cancer Hospital ( Site 3226)

    Fuzhou, Fujian, 350014, China

  • GEHO Muenster ( Site 0910)

    Münster, North Rhine-Westphalia, 48153, Germany

  • Gral Medical SRL-Medical Oncology ( Site 2511)

    Bucharest, Bucharest, 031422, Romania

  • Guys and St Thomas NHS Foundation Trust ( Site 1410)

    London, London, City of, SE1 9RT, United Kingdom

  • Gyeongsang National University Hospital ( Site 2804)

    Jinju, Kyongsangnam-do, 52727, South Korea

  • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2001)

    Istanbul, 34722, Turkey (Türkiye)

  • H.I.A. Sainte-Anne ( Site 0815)

    Toulon, Var, 83800, France

  • H.R.U Malaga - Hospital General ( Site 1206)

    Málaga, Malaga, 29011, Spain

  • H.U. Vall de Hebron ( Site 1201)

    Barcelona, 08035, Spain

  • Helse Stavanger HF Stavanger Universitetssjukehus ( Site 1103)

    Stavanger, Rogaland, 4011, Norway

  • Henan Cancer Hospital ( Site 3205)

    Zhengzhou, Henan, 450008, China

  • Henry Ford Hospital ( Site 0045)

    Detroit, Michigan, 48202, United States

  • Hopital Avicenne ( Site 0803)

    Bobigny, Seine-Saint-Denis, 93000, France

  • Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0500)

    Guadalajara, Jalisco, 44280, Mexico

  • Hospital Clinic de Barcelona ( Site 1204)

    Barcelona, 08036, Spain

  • Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 0604)

    Arequipa, Ariqipa, 04001, Peru

  • Hospital Nacional Cayetano Heredia ( Site 0602)

    Lima, 15102, Peru

  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez" ( Site 0508)

    Monterrey, Nuevo León, 64460, Mexico

  • Hospital Universitario La Fe ( Site 1203)

    Valencia, 46026, Spain

  • Hospital Universitario Puerta de Hierro (Majadahonda) ( Site 1202)

    Majadahonda, Madrid, 28222, Spain

  • Hospital Universitario Quiron Madrid ( Site 1200)

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Hospital Universitario Virgen Macarena ( Site 1205)

    Seville, 41009, Spain

  • Hospital of Lithuanian University of Health Sciences Kauno klinikos-Pulmonology ( Site 4201)

    Kaunas, Kaunas County, 50161, Lithuania

  • Hubei Cancer Hospital ( Site 3218)

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital ( Site 3225)

    Changsha, Hunan, 410013, China

  • Hunan Cancer Hospital ( Site 3238)

    Changsha, Hunan, 410013, China

  • IPOR Instituto Peruano de Oncología & Radioterapia ( Site 0606)

    Lima, 15036, Peru

  • Instituto Médico Río Cuarto ( Site 4003)

    Río Cuarto, Córdoba Province, X5800AEV, Argentina

  • Instituto Nacional de Cancerologia ( Site 0502)

    Tlalpan, 14080, Mexico

  • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2506)

    Cluj-Napoca, Cluj, 400015, Romania

  • Institutul Regional de Oncologie Iasi ( Site 2505)

    Iași, 700483, Romania

  • Istanbul Uni. Cerrahpasa Tip Fakultesi ( Site 2000)

    Istanbul, 34098, Turkey (Türkiye)

  • Istituto Clinico Humanitas Research Hospital ( Site 1000)

    Rozzano, Lombardy, 20089, Italy

  • Jiangsu Cancer Hospital ( Site 3234)

    Nanjing, Jiangsu, 210000, China

  • Jilin Cancer Hospital ( Site 3230)

    Changchun, Jilin, 130012, China

  • Johanna Etienne Hospital-Klinik für Onkologie ( Site 0916)

    Neuss, North Rhine-Westphalia, 41462, Germany

  • Johannes Wesling Klinikum Minden ( Site 0908)

    Minden, North Rhine-Westphalia, 32429, Germany

  • Juntendo University Hospital ( Site 3111)

    Tokyo, 113-0033, Japan

  • Kanagawa Cancer Center ( Site 3101)

    Yokohama, Kanagawa, 241-8515, Japan

  • Kangbuk Samsung Hospital ( Site 2806)

    Seoul, 03181, South Korea

  • Kansai Medical University Hospital ( Site 3103)

    Hirakata, Osaka, 573-1191, Japan

  • Katholisches Marienkrankenhaus gGmbH ( Site 0902)

    Hamburg, 22087, Germany

  • Keimyung University Dongsan Hospital CRC room 1 ( Site 2807)

    Daegu, Taegu-Kwangyokshi, 42601, South Korea

  • Kobe Minimally Invasive Cancer Center ( Site 3100)

    Kobe, Hyōgo, 650-0046, Japan

  • Krajska nemocnice Liberec, a.s. ( Site 2209)

    Liberec, 468 63, Czechia

  • Kurume University Hospital ( Site 3112)

    Kurume, Fukuoka, 830-0011, Japan

  • Kyiv City Clinical Oncology Center ( Site 2100)

    Kyiv, 03115, Ukraine

  • LLC Ukrainian Center of Tomotherapy ( Site 2105)

    Kropyvnytskyi, Kirovohrad Oblast, 25011, Ukraine

  • Leeds Teaching Hospitals NHS Trust ( Site 1401)

    Leeds, LS9 7TF, United Kingdom

  • Long Beach Memorial Medical Center ( Site 0006)

    Long Beach, California, 90806, United States

  • LungenClinic Grosshansdorf GmbH ( Site 0901)

    Großhansdorf, Schleswig-Holstein, 22927, Germany

  • MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 2500)

    Bucharest, Bucharest, 013823, Romania

  • MSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 1903)

    Moscow, Moscow, 125284, Russia

  • Masarykuv onkologicky ustav ( Site 2206)

    Brno, Brno-mesto, 656 53, Czechia

  • Massachusetts General Hospital ( Site 0038)

    Boston, Massachusetts, 02114, United States

  • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2404)

    Siedlce, Masovian Voivodeship, 08-110, Poland

  • McGill University Health Center - Research Institute ( Site 0114)

    Montreal, Quebec, H4A 3J1, Canada

  • Medical Center Verum ( Site 2106)

    Kyiv, Kyivska Oblast, 03039, Ukraine

  • Medical Center of Yuriy Spizhenko LLC.-Clinical Trial ( Site 2104)

    Kapitanivka Village, Kyivska Oblast, 08111, Ukraine

  • Medical center Medikal Plaza of Ecodnipro LLC ( Site 2107)

    Dnipro, Dnipropetrovsk Oblast, 49055, Ukraine

  • Medical institute named after Berezin Sergey ( Site 1906)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • Medipol Universite Hastanesi ( Site 2003)

    Istanbul, 34214, Turkey (Türkiye)

  • Memorial Ankara Hastanesi ( Site 2006)

    Ankara, 06520, Turkey (Türkiye)

  • Memorial Regional Hospital-Memorial Cancer Institute ( Site 0095)

    Hollywood, Florida, 33021, United States

  • Miami VA Healthcare System ( Site 0024)

    Miami, Florida, 33125, United States

  • Mid Florida Hematology and Oncology Center ( Site 0022)

    Orange City, Florida, 32763, United States

  • Montefiore Einstein Center ( Site 0083)

    The Bronx, New York, 10467, United States

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2402)

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Center ( Site 2800)

    Goyang-si, Kyonggi-do, 10408, South Korea

  • National Cancer Institute-Department of Thoracic Surgery and Oncology ( Site 4200)

    Vilnius, Vilniaus Miestas, 08660, Lithuania

  • National Hospital Organization Kyushu Cancer Center ( Site 3104)

    Fukuoka, 811-1395, Japan

  • Nemocnice Na Bulovce ( Site 2205)

    Prague, 180 81, Czechia

  • Nemocnice Na Plesi s.r.o. ( Site 2202)

    Nová Ves pod Pleší, Pribram, 262 04, Czechia

  • Niigata Cancer Center Hospital ( Site 3109)

    Niigata, 951-8566, Japan

  • Nizhniy Novgorod Region Oncology Dispensary ( Site 1914)

    Nizhny Novgorod, Nizhny Novgorod Oblast, 603081, Russia

  • North Estonia Medical Centre Foundation ( Site 1601)

    Tallinn, Harju, 13419, Estonia

  • Norton Brownsboro Hospital-Norton Cancer Institute - Brownsboro ( Site 0035)

    Louisville, Kentucky, 40241, United States

  • Novant Health Presbyterian ( Site 0081)

    Charlotte, North Carolina, 28204, United States

  • Oncocentro ( Site 0203)

    Viña del Mar, Valparaiso, 2520598, Chile

  • Oncosalud ( Site 0605)

    Lima, 15036, Peru

  • OrlandiOncologia ( Site 0201)

    Providencia, Region M. de Santiago, 7500713, Chile

  • Orlando Health, UF Health Cancer Center Inc ( Site 0092)

    Orlando, Florida, 32806, United States

  • Orszagos Koranyi Pulmonologiai Intezet ( Site 2305)

    Budapest, 1121, Hungary

  • Országos Korányi Pulmonológiai Intézet-VI. Tüdöbelosztály és Bronchológia ( Site 2309)

    Budapest, 1121, Hungary

  • Osaka International Cancer Institute ( Site 3106)

    Osaka, 541-8567, Japan

  • Osaka Medical and Pharmaceutical University Hospital ( Site 3110)

    Takatsuki, Osaka, 569-8686, Japan

  • Oslo Universitetssykehus HF. Ulleval ( Site 1100)

    Oslo, 0450, Norway

  • Parkview Research Center ( Site 0032)

    Fort Wayne, Indiana, 46845, United States

  • Pauls Stradins Clinical University Hospital ( Site 1501)

    Riga, 1002, Latvia

  • Peking Union Medical College Hospital ( Site 3201)

    Beijing, Beijing Municipality, 100006, China

  • Peking University Shenzhen Hospital ( Site 3216)

    Shenzhen, Guangdong, 518036, China

  • Petz Aladar Megyei Oktato Korhaz ( Site 2306)

    Győr, Győr-Moson-Sopron, 9024, Hungary

  • Piedmont Hematology-Oncology Associates ( Site 0080)

    Winston-Salem, North Carolina, 27103, United States

  • Pikeville Medical Center ( Site 0036)

    Pikeville, Kentucky, 41501, United States

  • Policlinica Oncomed SRL ( Site 2504)

    Timișoara, Timiș County, 300239, Romania

  • Policlinico Agostino Gemelli ( Site 1002)

    Rome, Lazio, 00168, Italy

  • Policlinico di Modena ( Site 1007)

    Modena, 41124, Italy

  • Queen Elizabeth II Health Sciences Centre ( Site 0100)

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Radiology Therapeutic Center-Oncology ( Site 2502)

    Otopeni, Ilfov, 075100, Romania

  • Ramathibodi Hospital. ( Site 3000)

    Bangkok, Bangkok, 10400, Thailand

  • Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 1911)

    Kazan', Tatarstan, Respublika, 420029, Russia

  • Riga East Clinical University Hospital ( Site 1500)

    Riga, 1079, Latvia

  • Royal Marsden Hospital (Sutton) ( Site 1407)

    London, Surrey, SM3 5PT, United Kingdom

  • Rutgers Cancer Institute of New Jersey ( Site 0054)

    New Brunswick, New Jersey, 08901, United States

  • S C Oncocenter Oncologie Clinica S R L-Medical Oncology ( Site 2509)

    Timișoara, Timiș County, 300166, Romania

  • S.C. Radiotherapy Center Cluj S.R.L ( Site 2503)

    Comuna Floresti, Cluj, 407280, Romania

  • SNPE National Cancer Institute ( Site 2101)

    Kyiv, Kyivska Oblast, 03022, Ukraine

  • SOGrigoriev Inst for Med Radiolgy and Oncology of NAMS of Ukraine-Clinical oncology and hematology ( Site 2110)

    Kharkiv, Kharkiv Oblast, 61024, Ukraine

  • SPZOZ MSWIA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie ( Site 2401)

    Olsztyn, Warmian-Masurian Voivodeship, 10-228, Poland

  • Sanford Cancer Center Oncology Clinic ( Site 0066)

    Sioux Falls, South Dakota, 57104, United States

  • Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1905)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • Second Xiangya Hospital of Central-South University ( Site 3227)

    Changsha, Hunan, 410011, China

  • Seoul National University Bundang Hospital ( Site 2801)

    Seongnam-si, Kyonggi-do, 13620, South Korea

  • Severance Hospital Yonsei University Health System ( Site 2808)

    Seoul, 03722, South Korea

  • Shanghai Chest Hospital ( Site 3207)

    Shanghai, Shanghai Municipality, 200030, China

  • Shanghai Pulmonary Hospital ( Site 3203)

    Shanghai, Shanghai Municipality, 200443, China

  • Showa Medical University Hospital ( Site 3105)

    Tokyo, 142-8666, Japan

  • Southampton General Hospital ( Site 1400)

    Southampton, Worcestershire, SO16 6YD, United Kingdom

  • Spitalul Clinic Judetean De Urgenta Constanta ( Site 2501)

    Constanța, 900591, Romania

  • Spitalul Universitar de Urgenta Bucuresti ( Site 2508)

    Bucharest, Bucharest, 050098, Romania

  • Srinagarind Hospital. Khon Kaen University ( Site 3002)

    Khon Kaen, 40002, Thailand

  • St Joseph Heritage Healthcare-Oncology ( Site 0088)

    Fullerton, California, 92835, United States

  • St. Bernards Medical Center ( Site 0089)

    Jonesboro, Arkansas, 72401, United States

  • St. Joseph Heritage Healthcare Local Lab ( Site 0011)

    Santa Rosa, California, 95403, United States

  • Sverdlovsk Regional Oncology Hospital ( Site 1909)

    Yekaterinburg, Sverdlovsk Oblast, 620036, Russia

  • Sykehuset Oestfold ( Site 1107)

    Grålum, Østfold fylke, 1714, Norway

  • Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 2400)

    Gdynia, Pomeranian Voivodeship, 81-519, Poland

  • Tartu University Hospital ( Site 1600)

    Tartu, Tartu, 50406, Estonia

  • The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 3232)

    Hangzhou, Zhejiang, 310003, China

  • The Catholic University of Korea St. Vincent s Hospital ( Site 2805)

    Suwon, Kyonggi-do, 16247, South Korea

  • The First Affiliated Hospital of Xiamen University ( Site 3219)

    Xiamen, Fujian, 361003, China

  • The Lindner Center for Research and Education at The Christ Hospital ( Site 0060)

    Cincinnati, Ohio, 45219, United States

  • The Second Affiliated Hospital of Nanchang University ( Site 3206)

    Nanchang, Jiangxi, 330006, China

  • Tianjin Medical University Cancer Institute & Hospital ( Site 3204)

    Tianjin, Tianjin Municipality, 300060, China

  • Tokyo Metropolitan Komagome Hospital ( Site 3108)

    Tokyo, 113-8677, Japan

  • Torrance Memorial Physician Network / Cancer Center ( Site 0093)

    Torrance, California, 90505, United States

  • UCLA Hematology/Oncology - Santa Monica ( Site 0013)

    Los Angeles, California, 90404, United States

  • Universitaetsklinikum Jena ( Site 0911)

    Jena, Thuringia, 07747, Germany

  • University College Hospital NHS Foundation Trust ( Site 1403)

    London-Camden, London, City of, NW1 2PG, United Kingdom

  • University of Kentucky ( Site 0096)

    Lexington, Kentucky, 40536, United States

  • University of South Alabama, Mitchell Cancer Institute ( Site 0003)

    Mobile, Alabama, 36604, United States

  • Universitätsmedizin Göttingen - Georg-August-Universität ( Site 0917)

    Göttingen, Lower Saxony, 37075, Germany

  • VA St. Louis Health Care System ( Site 0047)

    St Louis, Missouri, 63106, United States

  • Valley Health Systems - Ridgewood Campus ( Site 0056)

    Paramus, New Jersey, 07652, United States

  • Vestre Viken HF Drammen Sykehus ( Site 1101)

    Drammen, Buskerud, 3004, Norway

  • Veterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0075)

    Seattle, Washington, 98108, United States

  • Vseobecna fakultni nemocnice v Praze ( Site 2208)

    Prague, 128 08, Czechia

  • Washington University Siteman Cancer Center ( Site 0046)

    St Louis, Missouri, 63110, United States

  • West China Hospital of Sichuan University ( Site 3202)

    Chengdu, Sichuan, 510115, China

  • Weston Park Hospital ( Site 1406)

    Sheffield, Derbyshire, S10 2SJ, United Kingdom

  • Wuhan Union Hospital Cancer Center ( Site 3222)

    Wuhan, Hubei, 430022, China

  • Xiangya Hospital of Central South University ( Site 3637)

    Changsha, Hunan, 410008, China

  • Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 1910)

    Yaroslavl, Yaroslavl Oblast, 150054, Russia

  • Zentralklinik Bad Berka GmbH ( Site 0905)

    Bad Berka, Thuringia, 99437, Germany

  • Zhongshan Hospital Fudan University ( Site 3220)

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.